Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...

Paris: Sanofi has announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...